Table 4.
Adjusted Cox regression analysis of TSH prognostic groupings and survival from endometrial cancer.
| Thyroid Marker | Hazard Ratio (95% CI) | p-Value |
|---|---|---|
| Overall Survival | ||
| History of Hypothyroidism | ||
| No | 1.00 | |
| Yes | 0.22 (0.06, 0.74) | 0.02 |
| Baseline TSH (mU/L) | ||
| ≤4.5 | 1.00 | |
| >4.5 | 0.48 (0.14, 1.65) | 0.25 |
| Recurrence-free Survival | ||
| History of Hypothyroidism | ||
| No | 1.00 | |
| Yes | 0.17 (0.04, 0.77) | 0.02 |
| Baseline TSH (mU/L) | ||
| ≤4.5 | 1.00 | |
| >4.5 | 0.57 (0.16, 2.05) | 0.39 |
| Cancer-Specific Survival | ||
| History of Hypothyroidism | ||
| No | 1.00 | |
| Yes | 0.21 (0.05, 0.98) | 0.04 |
| Baseline TSH (mU/L) | ||
| ≤4.5 | 1.00 | |
| >4.5 | 0.38 (0.08, 1.82) | 0.23 |
Adjusted for age, body mass index, social class, history of diabetes, FIGO stage, grade and histological subtype, lymphovascular space invasion, depth of myometrial invasion. CI—confidence interval. TSH—thyroid-stimulating hormone. Bold values denote statistical significance at the p < 0.05 level.